{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:14:26Z","timestamp":1791357266253,"version":"4.3.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T00:00:00Z","timestamp":1594425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T00:00:00Z","timestamp":1594425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The relative benefits and risks of long-term maintenance treatment with antipsychotics have not been well studied in patients with bipolar disorder and major depressive disorder. For example, while antipsychotic dose reduction has been recommended in the management of serious side effects associated with antipsychotics, there is limited evidence on the impact of lowering doses on the course of underlying mood disorders.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective cohort study analyzed the impact of antipsychotic dose reduction in patients with bipolar disorder or major depressive disorder. Medical claims from six US states over a 6-year period were analyzed for patients with \u226510% or\u2009\u2265\u200930% reductions in antipsychotic dose (cases) and compared using survival analyses with matched controls receiving a stable dosage. Outcomes included hospitalizations for disease-specific mood disorders, other psychiatric disorders and all-cause emergency room visits, and claims for tardive dyskinesia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 23,992 patients with bipolar disorder and 17,766 with major depressive disorder had a\u2009\u2265\u200910% dose reduction, while 19,308 and 14,728, respectively, had a\u2009\u2265\u200930% dose reduction. In multivariate analyses, cases with a\u2009\u2265\u200910% dose reduction had a significantly increased risk of disease-specific admission (bipolar disorder: hazard ratio [95% confidence interval], 1.22 [1.15\u20131.31]; major depressive disorder: 1.22 [1.11\u20131.34]), other psychiatric admission (bipolar disorder: 1.19 [1.13\u20131.24]; major depressive disorder: 1.17 [1.11\u20131.23]), all-cause admission (bipolar disorder: 1.17 [1.12\u20131.23]; major depressive disorder: 1.11 [1.05\u20131.16]), and all-cause emergency room visits (bipolar disorder: 1.09 [1.05\u20131.13]; major depressive disorder: 1.07 [1.02\u20131.11]) (all <jats:italic>P<\/jats:italic>\u2009&lt;\u2009\u00a00.01). Similar results were observed following an \u226530% dose reduction. Dose reduction was not associated with decreased claims for tardive dyskinesia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Patients with mood disorders who had antipsychotic dose reductions showed small but statistically significant increases in all-cause and mental health-related hospitalizations, which may lead to increased healthcare costs. These results highlight the need for additional long-term studies of the necessity and safety of maintenance antipsychotic treatment in mood disorders.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-020-02748-0","type":"journal-article","created":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T04:52:57Z","timestamp":1594443177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Hospital utilization rates following antipsychotic dose reduction in mood disorders: implications for treatment of tardive dyskinesia"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2840-4763","authenticated-orcid":false,"given":"Stanley N.","family":"Caroff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Ayyagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Abler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,11]]},"reference":[{"key":"2748_CR1","unstructured":"National Institute of Mental Health. Bipolar disorder [https:\/\/www.nimh.nih.gov\/health\/statistics\/bipolar-disorder.shtml]. Last update November 2017. Accessed 21 May 2020."},{"key":"2748_CR2","unstructured":"American Psychiatric Association. Depression [https:\/\/www.psychiatry.org\/patients-families\/depression\/what-is-depression]. Last update January 2017. Accessed 21 May 2020."},{"issue":"2","key":"2748_CR3","first-page":"121","volume":"20","author":"KN Fountoulakis","year":"2017","unstructured":"Fountoulakis KN, Yatham L, Grunze H, Vieta E, Young A, Blier P, Kasper S, Moeller HJ. The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 2: review, grading of the evidence, and a precise algorithm. Int J Neuropsychopharmacol. 2017;20(2):121\u201379.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"Suppl 1","key":"2748_CR4","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1016\/S0165-0327(14)70007-2","volume":"169","author":"DE Kemp","year":"2014","unstructured":"Kemp DE. Managing the side effects associated with commonly used treatments for bipolar depression. J Affect Disord. 2014;169(Suppl 1):S34\u201344.","journal-title":"J Affect Disord"},{"issue":"3","key":"2748_CR5","first-page":"36","volume":"2","author":"M Mathews","year":"2005","unstructured":"Mathews M, Gratz S, Adetunji B, George V, Mathews M, Basil B. Antipsychotic-induced movement disorders: evaluation and treatment. Psychiatry (Edgmont). 2005;2(3):36\u201341.","journal-title":"Psychiatry (Edgmont)"},{"issue":"2","key":"2748_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/wps.20204","volume":"14","author":"CU Correll","year":"2015","unstructured":"Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14(2):119\u201336.","journal-title":"World Psychiatry"},{"issue":"2","key":"2748_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/YCO.0b013e3282f53132","volume":"21","author":"CU Correll","year":"2008","unstructured":"Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatr. 2008;21(2):151\u20136.","journal-title":"Curr Opin Psychiatr"},{"issue":"3","key":"2748_CR8","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.4088\/JCP.16r10832","volume":"78","author":"M Carbon","year":"2017","unstructured":"Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatr. 2017;78(3):e264\u201378.","journal-title":"J Clin Psychiatr"},{"key":"2748_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jns.2018.02.007","volume":"389","author":"A D'Abreu","year":"2018","unstructured":"D'Abreu A, Akbar U, Friedman JH. Tardive dyskinesia: epidemiology. J Neurol Sci. 2018;389:17\u201320.","journal-title":"J Neurol Sci"},{"issue":"3","key":"2748_CR10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.psc.2016.04.003","volume":"39","author":"SN Caroff","year":"2016","unstructured":"Caroff SN, Campbell EC. Drug-induced extrapyramidal syndromes: implications for contemporary practice. Psychiatr Clin North Am. 2016;39(3):391\u2013411.","journal-title":"Psychiatr Clin North Am"},{"issue":"Suppl 4","key":"2748_CR11","first-page":"33","volume":"61","author":"PE Keck Jr","year":"2000","unstructured":"Keck PE Jr, McElroy SL, Strakowski SM, Soutullo CA. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J Clin Psychiatry. 2000;61(Suppl 4):33\u20138.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"2748_CR12","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.jad.2013.04.053","volume":"150","author":"J Coplan","year":"2013","unstructured":"Coplan J, Gugger JJ, Tasleem H. Tardive dyskinesia from atypical antipsychotic agents in patients with mood disorders in a clinical setting. J Affect Disord. 2013;150(3):868\u201371.","journal-title":"J Affect Disord"},{"issue":"9799","key":"2748_CR13","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S0140-6736(11)60873-8","volume":"378","author":"A Cipriani","year":"2011","unstructured":"Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, Purgato M, Spineli LM, Goodwin GM, Geddes JR. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet. 2011;378(9799):1306\u201315.","journal-title":"Lancet"},{"issue":"8","key":"2748_CR14","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1592\/phco.26.8.1134","volume":"26","author":"MJ Ehret","year":"2006","unstructured":"Ehret MJ, Levin GM. Long-term use of atypical antipsychotics in bipolar disorder. Pharmacotherapy. 2006;26(8):1134\u201347.","journal-title":"Pharmacotherapy"},{"key":"2748_CR15","doi-asserted-by":"crossref","unstructured":"Butler M, Urosevic S, Desai P, Sponheim SR, Popp J, Nelson VA, Thao V, Sunderlin B. In: Treatment for Bipolar Disorder in Adults: A Systematic Review. Rockville (MD): Agency for Healthcare Research and Quality; 2018.","DOI":"10.23970\/AHRQEPCCER208"},{"issue":"Suppl 2","key":"2748_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/bdi.12698","volume":"20","author":"P Boyce","year":"2018","unstructured":"Boyce P, Irwin L, Morris G, Hamilton A, Mulder R, Malhi GS, Porter RJ. Long-acting injectable antipsychotics as maintenance treatments for bipolar disorder-a critical review of the evidence. Bipolar Disord. 2018;20(Suppl 2):25\u201336.","journal-title":"Bipolar Disord"},{"issue":"6","key":"2748_CR17","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/acps.12717","volume":"135","author":"GB Parker","year":"2017","unstructured":"Parker GB, Graham RK, Tavella G. Is there consensus across international evidence-based guidelines for the management of bipolar disorder? Acta Psychiatr Scand. 2017;135(6):515\u201326.","journal-title":"Acta Psychiatr Scand"},{"key":"2748_CR18","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2147\/NDT.S18333","volume":"7","author":"RM Berman","year":"2011","unstructured":"Berman RM, Thase ME, Trivedi MH, Hazel JA, Marler SV, McQuade RD, Carson W, Baker RA, Marcus RN. Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. Neuropsychiatr Dis Treat. 2011;7:303\u201312.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"6","key":"2748_CR19","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1001\/archpsyc.1984.01790170097011","volume":"41","author":"WM Glazer","year":"1984","unstructured":"Glazer WM, Moore DC, Schooler NR, Brenner LM, Morgenstern H. Tardive dyskinesia. A discontinuation study. Arch Gen Psychiatry. 1984;41(6):623\u20137.","journal-title":"Arch Gen Psychiatry"},{"key":"2748_CR20","doi-asserted-by":"crossref","first-page":"266","DOI":"10.5334\/tohm.199","volume":"4","author":"D Zutshi","year":"2014","unstructured":"Zutshi D, Cloud LJ, Factor SA. Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: experience from a university-based movement disorder clinic. Tremor Other Hyperkinet Mov (N Y). 2014;4:266.","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"issue":"2","key":"2748_CR21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1176\/ps.44.2.190","volume":"44","author":"MP Caligiuri","year":"1992","unstructured":"Caligiuri MP. Tardive dyskinesia: a task force report of the American Psychiatric Association. Psychiatr Serv. 1992;44(2):190.","journal-title":"Psychiatr Serv"},{"issue":"9","key":"2748_CR22","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1080\/14737175.2017.1361322","volume":"17","author":"H Salem","year":"2017","unstructured":"Salem H, Pigott T, Zhang XY, Zeni CP, Teixeira AL. Antipsychotic-induced tardive dyskinesia: from biological basis to clinical management. Expert Rev Neurother. 2017;17(9):883\u201394.","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"2748_CR23","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12888-018-1889-2","volume":"18","author":"SN Caroff","year":"2018","unstructured":"Caroff SN, Mu F, Ayyagari R, Schilling T, Abler V, Carroll B. Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia. BMC Psychiatry. 2018;18(1):306.","journal-title":"BMC Psychiatry"},{"key":"2748_CR24","first-page":"CD000459","volume":"2","author":"H Bergman","year":"2018","unstructured":"Bergman H, Rathbone J, Agarwal V, Soares-Weiser K. Antipsychotic reduction and\/or cessation and antipsychotics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev. 2018;2:CD000459.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"2748_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1055\/s-2007-971169","volume":"27","author":"K Soares-Weiser","year":"2007","unstructured":"Soares-Weiser K, Fernandez HH. Tardive dyskinesia. Semin Neurol. 2007;27(2):159\u201369.","journal-title":"Semin Neurol"},{"key":"2748_CR26","unstructured":"Work Group on Major Depressive Disorder. Practice guideline for the treatment of patients with major depressive disorder 2010. [http:\/\/psychiatryonline.org\/pb\/assets\/raw\/sitewide\/practice_guidelines\/guidelines\/mdd.pdf] Accessed 21 May 2020."},{"issue":"6","key":"2748_CR27","first-page":"379","volume":"5","author":"JG Bergeson","year":"2012","unstructured":"Bergeson JG, Kalsekar I, Jing Y, You M, Forbes RA, Hebden T. Medical care costs and hospitalization in patients with bipolar disorder treated with atypical antipsychotics. Am Health Drug Benefits. 2012;5(6):379\u201386.","journal-title":"Am Health Drug Benefits"},{"issue":"10","key":"2748_CR28","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/S0149-2918(02)80070-4","volume":"24","author":"M Stender","year":"2002","unstructured":"Stender M, Bryant-Comstock L, Phillips S. Medical resource use among patients treated for bipolar disorder: a retrospective, cross-sectional, descriptive analysis. Clin Ther. 2002;24(10):1668\u201376.","journal-title":"Clin Ther"},{"issue":"10","key":"2748_CR29","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1176\/ps.50.10.1303","volume":"50","author":"GE Simon","year":"1999","unstructured":"Simon GE, Unutzer J. Health care utilization and costs among patients treated for bipolar disorder in an insured population. Psychiatr Serv. 1999;50(10):1303\u20138.","journal-title":"Psychiatr Serv"},{"issue":"2","key":"2748_CR30","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4088\/JCP.14m09298","volume":"76","author":"PE Greenberg","year":"2015","unstructured":"Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76(2):155\u201362.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"2748_CR31","first-page":"323","volume":"18","author":"T Suzuki","year":"2003","unstructured":"Suzuki T, Uchida H, Tanaka KF, Tomita M, Tsunoda K, Nomura K, Takano H, Tanabe A, Watanabe K, Yagi G, et al. Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia. Int Clin Psychopharmacol. 2003;18(6):323\u20139.","journal-title":"Int Clin Psychopharmacol"},{"issue":"10","key":"2748_CR32","doi-asserted-by":"publisher","first-page":"e25588","DOI":"10.1371\/journal.pone.0025588","volume":"6","author":"PR Bakker","year":"2011","unstructured":"Bakker PR, de Groot IW, van Os J, van Harten PN. Long-stay psychiatric patients: a prospective study revealing persistent antipsychotic-induced movement disorder. PLoS One. 2011;6(10):e25588.","journal-title":"PLoS One"},{"issue":"2\u20133","key":"2748_CR33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0920-9964(95)00096-8","volume":"19","author":"PN van Harten","year":"1996","unstructured":"van Harten PN, Matroos GE, Hoek HW, Kahn RS. The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia the curacao extrapyramidal syndromes study: I. Schizophr Res. 1996;19(2\u20133):195\u2013203.","journal-title":"Schizophr Res"},{"issue":"1","key":"2748_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/070674370404900105","volume":"49","author":"L Cortese","year":"2004","unstructured":"Cortese L, Jog M, McAuley TJ, Kotteda V, Costa G. Assessing and monitoring antipsychotic-induced movement disorders in hospitalized patients: a cautionary study. Can J Psychiatr. 2004;49(1):31\u20136.","journal-title":"Can J Psychiatr"},{"key":"2748_CR35","doi-asserted-by":"crossref","unstructured":"Kleinbaum D, Klein M. Survival analysis: a self-learning text. 3rd ed. New York, NY: Springer; 2012.","DOI":"10.1007\/978-1-4419-6646-9"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02748-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-020-02748-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02748-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T23:25:37Z","timestamp":1625959537000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-020-02748-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,11]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2748"],"URL":"https:\/\/doi.org\/10.1186\/s12888-020-02748-0","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,11]]},"assertion":[{"value":"30 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The database complies with the privacy rules of the Health Insurance Portability and Accountability Act. This retrospective database analysis was granted an exemption by the New England Independent Review Board on August 31, 2017. As all pre-existing data within the database were anonymized, no informed consent was required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"<b>SNC<\/b>: Consultant for Teva Pharmaceuticals, Neurocrine Biosciences, Inc., Osmotica Pharmaceuticals, and DisperSol Technologies; received a research grant from Neurocrine Biosciences, Inc.<b>FM<\/b>: Employee of Analysis Group, Inc.<b>RA<\/b>: Employee of Analysis Group, Inc.<b>TS<\/b>: Employee of Teva Branded Pharmaceutical Products R&D, Inc.<b>VA<\/b>: Former employee of Teva Pharmaceuticals.<b>BC<\/b>: Employee of Teva Branded Pharmaceutical Products R&D, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"365"}}